Top

Journal of Assisted Reproduction and Genetics

Published in:

01-11-2012 | ASSISTED REPRODUCTION TECHNOLOGIES

Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial

Authors: Tahereh Madani, Ladan Mohammadi Yeganeh, Shabnam Khodabakhshi, Mohammad Reza Akhoond, Fatemeh Hasani

Published in: Journal of Assisted Reproduction and Genetics | Issue 11/2012

Abstract

Purpose

To investigate the effect of late follicular administration of low dose hCG on oocyte maturity in poor responding women undergoing intracytoplasmic sperm injection (ICSI).

Materials and methods

This prospective randomized pilot trial was performed on 73 poor responders undergoing ICSI, in Reproductive Biomedicine Research Center, Royan Institute, Tehran, Iran. All eligible patients underwent a GnRH-a long protocol and were randomly allocated into three study groups for ovarian stimulation: groupA received recombinant FSH alone, group B received recombinant FSH supplemented by 100 IU hCG. Group C received recombinant FSH supplemented by 200 IU hCG. The main endpoint was the number of metaphase II oocytes retrieved.

Results

Of 78 poor responding patients entered to this study, 73 women were considered eligible for enrolment. Of these, 26 women were allocated to receive only recombinant FSH, 24 patients allocated to receive recombinant FSH and 100 IU hCG and 23 patients were assigned to receive recombinant FSH and 200 IU hCG. Number of oocytes retrieved were significantly higher in group B compared to group A (6.5 ± 3.3 versus 4.0 ± 2.3; P = .03). Other cycle and clinical outcomes were comparable between three groups.

Conclusions

The present study demonstrated that adding 100 IU hCG to rFSH in a GnRH agonist cycle in poor responders improve response to stimulation whereas the number of metaphase II oocytes remains comparable between groups. The existence of a possible trend toward higher mature oocytes and lower total dosage rFSH in patients received 100 or 200 IU hCG is probably due to the small sample size that means further large clinical trials in a more homogenous population is required (clinical trial registration number; NCT01509833).

Keay SD, Liversedge NH, Mathur RS, Jenkins JM. Assisted conception following poor ovarian response to gonadotrophin stimulation. Br J Obstet Gynaecol. 1997;104(5):521–7.PubMedCrossRef

Pellicer A, Lightman A, Diamond MP, Russell JB, DeCherney AH. Outcome of in vitro fertilization in women with low response to ovarian stimulation. Fertil Steril. 1987;47(5):812–5.PubMed

Padhy N, Gupta S, Mahla A, Latha M, Varma T. Demographic characteristics and clinical profile of poor responders in IVF/ICSI: a comparative study. J Hum Reprod Sci. 2010;3(2):91–4.PubMedCrossRef

Coccia ME, Rizzello F, Mariani G, Bulletti C, Palagiano A, Scarselli G. Impact of endometriosis on in vitro fertilization and embryo transfer cycles in young women: a stage-dependent interference. Acta Obstet Gynecol Scand. 2011;90(11):1232–8.PubMedCrossRef

Keay SD, Barlow R, Eley A, Masson GM, Anthony FW, Jenkins JM. The relation between immunoglobulin G antibodies to Chlamydia trachomatis and poor ovarian response to gonadotropin stimulation before in vitro fertilization. Fertil Steril. 1998;70(2):214–8.PubMedCrossRef

Lamazou F, Fuchs F, Grynberg M, Gallot V, Herzog E, Fanchin R, et al. [Cancellation of IVF-ET cycles: poor prognosis, poor responder, or variability of the response to controlled ovarian hyperstimualtion? an analysis of 142 cancellations.]. J Gynecol Obstet Biol Reprod (Paris). 2011. Abstract.

Vollenhoven B, Osianlis T, Catt J. Is there an ideal stimulation regimen for IVF for poor responders and does it change with age? J Assist Reprod Genet. 2008;25(11–12):523–9.PubMedCrossRef

Gurgan T, Demirol A. Recombinant luteinizing hormone in assisted reproductive technology. Rev Gynaecol Pract. 2005;5(1):45–50.CrossRef

Esposito MA, Barnhart KT, Coutifaris C, Patrizio P. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil Steril. 2001;75(3):519–24.PubMedCrossRef

10.

Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod. 2000;15(5):1003–8.PubMedCrossRef

11.

O'Dea L, O'Brien F, Currie K, Hemsey G. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin. 2008;24(10):2785–93.PubMedCrossRef

12.

Shoham Z, Smith H, Yeko T, O'Brien F, Hemsey G, O'Dea L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf). 2008;69(3):471–8.CrossRef

13.

The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab. 1998;83(5):1507–14.CrossRef

14.

Burgues S. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod. 2001;16(12):2525–32.PubMedCrossRef

15.

Matorras R, Prieto B, Exposito A, Mendoza R, Crisol L, Herranz P, et al. Mid-follicular LH supplementation in women aged 35–39 years undergoing ICSI cycles: a randomized controlled study. Reprod Biomed Online. 2011;22 Suppl 1:S43–51.PubMedCrossRef

16.

Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao Ch V, Tesarik J, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril. 2005;84(2):275–84.PubMedCrossRef

17.

Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT, et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab. 1999;84(8):2659–63.PubMedCrossRef

18.

Serafini P, Yadid I, Motta EL, Alegretti JR, Fioravanti J, Coslovsky M. Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial. Fertil Steril. 2006;86(4):830–8.PubMedCrossRef

19.

Blockeel C, De Vos M, Verpoest W, Stoop D, Haentjens P, Devroey P. Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? a pilot study. Hum Reprod. 2009;24(11):2910–6.PubMedCrossRef

20.

Kosmas IP, Zikopoulos K, Georgiou I, Paraskevaidis E, Blockeel C, Tournaye H, et al. Low-dose HCG may improve pregnancy rates and lower OHSS in antagonist cycles: a meta-analysis. Reprod Biomed Online. 2009;19(5):619–30.PubMedCrossRef

21.

Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT. Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea. Fertil Steril. 1999;72(6):1118–20.PubMedCrossRef

22.

Berkkanoglu M, Isikoglu M, Aydin D, Ozgur K. Clinical effects of ovulation induction with recombinant follicle-stimulating hormone supplemented with recombinant luteinizing hormone or low-dose recombinant human chorionic gonadotropin in the midfollicular phase in microdose cycles in poor responders. Fertil Steril. 2007;88(3):665–9.PubMedCrossRef

23.

Chung K, Krey L, Katz J, Noyes N. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists. Fertil Steril. 2005;84(2):313–8.PubMedCrossRef

24.

Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod. 2005;20(5):1200–6.PubMedCrossRef

25.

Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril. 2006;85(4):925–31.PubMedCrossRef

26.

World Health Organization. Laboratory manual of the WHO for the examination of human semen and sperm-cervical mucus interaction. Ann Ist Super Sanita. 2001;37(1):I–XII. 1–123.

27.

Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci. 1988;541:259–74.PubMedCrossRef

28.

Rezazadeh Valojerdi M, Eftekhari-Yazdi P, Karimian L, Hassani F, Movaghar B. Vitrification versus slow freezing gives excellent survival, post warming embryo morphology and pregnancy outcomes for human cleaved embryos. J Assist Reprod Genet. 2009;26(6):347–54.PubMedCrossRef

29.

Sullivan MW, Stewart-Akers A, Krasnow JS, Berga SL, Zeleznik AJ. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab. 1999;84(1):228–32.PubMedCrossRef

30.

Campbell BK, Dobson H, Baird DT, Scaramuzzi RJ. Studies on the role of LH in the maturation of the pre-ovulatory follicle in a sheep using a GnRH-antagonist. Anim Reprod Sci. 1997;48(2–4):219–34.PubMedCrossRef

31.

Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod. 1998;13(7):1788–92.PubMedCrossRef

32.

Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril. 2004;82(6):1521–6.PubMedCrossRef

33.

Drakakis P, Loutradis D, Beloukas A, Sypsa V, Anastasiadou V, Kalofolias G, et al. Early hCG addition to rFSH for ovarian stimulation in IVF provides better results and the cDNA copies of the hCG receptor may be an indicator of successful stimulation. Reprod Biol Endocrinol. 2009;7:110.PubMedCrossRef

34.

Filicori M, Cognigni GE, Taraborrelli S, Parmegiani L, Bernardi S, Ciampaglia W. Intracytoplasmic sperm injection pregnancy after low-dose human chorionic gonadotropin alone to support ovarian folliculogenesis. Fertil Steril. 2002;78(2):414–6.PubMedCrossRef

35.

Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005;84(2):394–401.PubMedCrossRef

36.

Caglar GS, Asimakopoulos B, Nikolettos N, Diedrich K, Al-Hasani S. Recombinant LH in ovarian stimulation. Reprod Biomed Online. 2005;10(6):774–85.PubMedCrossRef

37.

Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online. 2004;8(6):635–43.PubMedCrossRef

38.

Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri MG, et al. Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod Biomed Online. 2001;3(3):190–4.PubMedCrossRef

39.

Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Pellicer A. Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis. Fertil Steril. 2011;95(3):1031–6.PubMedCrossRef

40.

Ferrari B, Barusi L, Coppola F. Clinical and endocrine effects of ovulation induction with FSH and hCG supplementation in low responders in the midfollicular phase. A pilot study. J Reprod Med. 2002;47(2):137–43.PubMed

41.

Laml T, Obruca A, Fischl F, Huber JC. Recombinant luteinizing hormone in ovarian hyperstimulation after stimulation failure in normogonadotropic women. Gynecol Endocrinol. 1999;13(2):98–103.PubMedCrossRef

42.

Loutradis D, Elsheikh A, Kallianidis K, Drakakis P, Stefanidis K, Milingos S, et al. Results of controlled ovarian stimulation for ART in poor responders according to the short protocol using different gonadotrophins combinations. Arch Gynecol Obstet. 2004;270(4):223–6.PubMedCrossRef

43.

Bjercke S, Tanbo T, Abyholm T, Omland A, Opoien HK, Fedorcsak P. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing their first treatment cycle of IVF or ICSI. Acta Obstet Gynecol Scand. 2010;89(8):1053–60.PubMedCrossRef

44.

Hompes PG, Broekmans FJ, Hoozemans DA, Schats R. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril. 2008;89(6):1685–93.PubMedCrossRef

45.

Koichi K, Yukiko N, Shima K, Sachiko S. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol. J Assist Reprod Genet. 2006;23(5):223–8.PubMedCrossRef

46.

Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? a systematic review and meta-analysis. Hum Reprod Update. 2007;13(5):445–52.PubMedCrossRef

47.

Van Horne AK, Bates Jr GW, Robinson RD, Arthur NJ, Propst AM. Recombinant follicle-stimulating hormone (rFSH) supplemented with low-dose human chorionic gonadotropin compared with rFSH alone for ovarian stimulation for in vitro fertilization. Fertil Steril. 2007;88(4):1010–3.PubMedCrossRef

48.

Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011;26(7):1616–24.PubMedCrossRef

Title: Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial
Authors: Tahereh Madani
Ladan Mohammadi Yeganeh
Shabnam Khodabakhshi
Mohammad Reza Akhoond
Fatemeh Hasani
Publication date: 01-11-2012
Publisher: Springer US
Published in: Journal of Assisted Reproduction and Genetics / Issue 11/2012
Print ISSN: 1058-0468
Electronic ISSN: 1573-7330
DOI: https://doi.org/10.1007/s10815-012-9854-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Efficacy of low dose hCG on oocyte maturity for ovarian stimulation in poor responder women undergoing intracytoplasmic sperm injection cycle: a randomized controlled trial

Abstract

Purpose

Materials and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2012

Risk evaluation and preimplantation genetic diagnosis in an infertile man with an unbalanced translocation t(10;15) resulting in a healthy baby

The follicular microenviroment as a predictor of pregnancy: MALDI-TOF MS lipid profile in cumulus cells

A comparative study on oxidative and antioxidative markers of serum and follicular fluid in GnRH agonist and antagonist cycles

A review of, and commentary on, the ongoing second clinical introduction of preimplantation genetic screening (PGS) to routine IVF practice

Angiotensin-converting enzyme insertion/deletion (I/D) polymorphisms and recurrent pregnancy loss: a meta-analysis

Early initiation of gonadotropin-releasing hormone antagonist in polycystic ovarian syndrome patients undergoing assisted reproduction: randomized controlled trial ISRCTN69937179